Genmab A/S (NASDAQ:GMAB) Stock Position Reduced by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 35.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,615 shares of the company's stock after selling 24,894 shares during the period. Dimensional Fund Advisors LP's holdings in Genmab A/S were worth $952,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in GMAB. Crossmark Global Holdings Inc. increased its holdings in shares of Genmab A/S by 8.8% in the 4th quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company's stock valued at $868,000 after acquiring an additional 3,377 shares during the last quarter. SG Americas Securities LLC raised its stake in Genmab A/S by 82.7% during the 4th quarter. SG Americas Securities LLC now owns 26,396 shares of the company's stock worth $551,000 after acquiring an additional 11,949 shares in the last quarter. Blue Trust Inc. raised its stake in Genmab A/S by 33.4% during the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock worth $120,000 after acquiring an additional 1,442 shares in the last quarter. R Squared Ltd purchased a new position in shares of Genmab A/S during the fourth quarter worth about $93,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock valued at $186,000 after purchasing an additional 827 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on GMAB shares. HC Wainwright reissued a "buy" rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a research note on Thursday, February 13th. Finally, Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Trading Up 0.9%

Shares of Genmab A/S stock opened at $20.52 on Thursday. The company has a fifty day moving average price of $19.75 and a 200 day moving average price of $20.72. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $30.06. The stock has a market cap of $13.16 billion, a price-to-earnings ratio of 11.79, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The business had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.